Galmed Pharmaceuticals Ltd.
GLMD
$0.52
-$0.01-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.69M | 3.64M | 3.26M | 3.53M | 3.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.29M | 8.51M | 7.11M | 7.03M | 6.14M |
| Operating Income | -9.29M | -8.51M | -7.11M | -7.03M | -6.14M |
| Income Before Tax | -11.12M | -10.31M | -8.70M | -8.72M | -7.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.12 | -10.31 | -8.70 | -8.72 | -7.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.12M | -10.31M | -8.70M | -8.72M | -7.35M |
| EBIT | -9.29M | -8.51M | -7.11M | -7.03M | -6.14M |
| EBITDA | -7.18M | -8.43M | -7.05M | -6.99M | -6.05M |
| EPS Basic | -2.07 | -2.40 | -3.60 | -5.56 | -6.58 |
| Normalized Basic EPS | -1.00 | -1.21 | -1.72 | -2.94 | -3.66 |
| EPS Diluted | -2.07 | -2.40 | -3.60 | -5.56 | -6.58 |
| Normalized Diluted EPS | -1.00 | -1.21 | -1.72 | -2.94 | -3.66 |
| Average Basic Shares Outstanding | 22.02M | 17.20M | 12.80M | 8.17M | 4.90M |
| Average Diluted Shares Outstanding | 22.02M | 17.20M | 12.80M | 8.17M | 4.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |